- Home
- FLNC vs AKRO Comparison
FLNC vs AKRO Comparison
Compare FLNC & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLNC
- AKRO
- Stock Information
- Founded
- FLNC 2018
- AKRO 2017
- Country
- FLNC United States
- AKRO United States
- Employees
- FLNC N/A
- AKRO N/A
- Industry
- FLNC Industrial Machinery/Components
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- FLNC Miscellaneous
- AKRO Health Care
- Exchange
- FLNC Nasdaq
- AKRO Nasdaq
- Market Cap
- FLNC 969.5M
- AKRO 3.6B
- IPO Year
- FLNC 2021
- AKRO 2019
- Fundamental
- Price
- FLNC $7.95
- AKRO $46.20
- Analyst Decision
- FLNC Hold
- AKRO Strong Buy
- Analyst Count
- FLNC 19
- AKRO 8
- Target Price
- FLNC $8.47
- AKRO $80.38
- AVG Volume (30 Days)
- FLNC 4.3M
- AKRO 978.3K
- Earning Date
- FLNC 08-11-2025
- AKRO 11-07-2025
- Dividend Yield
- FLNC N/A
- AKRO N/A
- EPS Growth
- FLNC N/A
- AKRO N/A
- EPS
- FLNC N/A
- AKRO N/A
- Revenue
- FLNC $2,449,087,000.00
- AKRO N/A
- Revenue This Year
- FLNC N/A
- AKRO N/A
- Revenue Next Year
- FLNC $21.59
- AKRO N/A
- P/E Ratio
- FLNC N/A
- AKRO N/A
- Revenue Growth
- FLNC 14.26
- AKRO N/A
- 52 Week Low
- FLNC $3.46
- AKRO $21.34
- 52 Week High
- FLNC $24.00
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- FLNC 56.49
- AKRO 51.07
- Support Level
- FLNC $7.26
- AKRO $41.80
- Resistance Level
- FLNC $8.30
- AKRO $45.44
- Average True Range (ATR)
- FLNC 0.48
- AKRO 1.97
- MACD
- FLNC 0.11
- AKRO 0.06
- Stochastic Oscillator
- FLNC 79.09
- AKRO 74.58
About FLNC Fluence Energy Inc.
Fluence Energy Inc is enabling the global clean energy transition with market-leading energy storage products and services, and digital applications for renewables and storage. Geographically, it derives a majority of its revenue from the Americas.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.